Methotrexate and its effect on the anti-GAD titre in two patients with rheumatoid arthritis and diabetes mellitus

Annals of the Rheumatic Diseases

Volumn 67, Issue 7, 2008, Pages 1051-1052

  Van Deutekom, A W ^a   Nurmohamed, M T ^a,b   Peters, M J L ^a,b   Van Eijk, I C ^b   Dijkmans, B A C ^a,b   Hamann, D ^c   Heine, R J ^a   Simsek, S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JAN VAN BREEMEN INSTITUTE   (Netherlands)

^c Sanquin Diagnostiek   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE ANTIBODY; INSULIN; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; AGED; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; LETTER; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT FAILURE;

AGED; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MIDDLE AGED;

EID: 46849105303     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.082198     Document Type: Letter

References (10)

1. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001;60:729-35.
2. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. Drugs 2005;65:661-94.
3. Spadaro A, Riccieri V, Sili SA, Taccari E, Zoppini A. One year treatment with low dose methotrexate in rheumatoid arthritis: effect on class specific rheumatoid factors. Clin Rheumatol 1993;12:357-60.
4. Alarcon GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ. Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis. Evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 1990;33:1156-61.
5. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993;42:359-62.
6. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997;350:1288-93.
7. Torn C, Landin-Olsson M, Ostman J, Schersten B, Arnqvist H, Blohme G, et al. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 2000;16:442-7.
8. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995;18:1557-65.
9. Decochez K, Tits J, Coolens JL, Van Gaal L, Krzentowski G, Winnock F, et al. The Belgian Diabetes Registry. High frequency of persisting or increasing islet-specific autoantibody levels after diagnosis of type 1 diabetes presenting before 40 years of age. Diabetes Care 2000;23:838-44.
10. Borg H, Gottsäter A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and β-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002;51:1754-62.